IBN Announces Latest Episode of The Bell2Bell Podcast Featuring Annovis Bio CEO Dr. Maria Maccecchini, Live from AAIC 2024
August 05 2024 - 8:00AM
via IBN – IBN, a multifaceted communications organization engaged
in connecting public companies to the investment community, is
excited to announce the release of the latest episode of The
Bell2Bell Podcast, recorded live from the Alzheimer’s Association
International Conference® 2024 (AAIC®) in Philadelphia. This
release is part of IBN’s ongoing efforts to provide specialized
content distribution via widespread syndication channels.
The Bell2Bell Podcast delivers informative updates and exclusive
interviews with executives operating in fast-moving industries.
Bell2Bell’s latest podcast features Dr. Maria Maccecchini, Ph.D.,
Founder, President, and CEO of Annovis Bio Inc. (NYSE: ANVS), a
late-stage clinical drug platform company pioneering transformative
therapies for neurodegenerative diseases such as Alzheimer’s
disease (AD) and Parkinson’s disease (PD).
Broadcasting live from AAIC 2024, Dr. Maccecchini delves into
the detailed findings from Annovis Bio’s recent Phase 3 Parkinson’s
study of its lead drug candidate, buntanetap. During the interview,
she provides insights into how the scientific community is reacting
to the promising data and what it could mean for the future of
neurodegenerative disease treatment. Additionally, Dr. Maccecchini
discusses Annovis Bio’s strategic plans moving forward, including
potential regulatory milestones and upcoming clinical trials that
aim to further validate the efficacy and safety of buntanetap in
treating both Parkinson’s and Alzheimer’s diseases.
“Our Phase 3 data indicate that buntanetap has the potential to
significantly improve the quality of life for Parkinson’s
patients,” said Dr. Maccecchini during the interview. “Being able
to share these findings live from AAIC, one of the most prestigious
events in Alzheimer’s and Parkinson’s research, underscores the
importance of our work and the promise it holds for patients.”
Join IBN’s Stuart Smith and Dr. Maria Maccecchini to learn more
about Annovis Bio’s recent achievements, the next steps for
buntanetap, and the company’s future goals.
To hear the episode and subscribe for future podcasts,
visit https://podcast.bell2bell.com.
The latest installment of The Bell2Bell Podcast continues to
reinforce IBN’s commitment to the expansion of its robust network
of brands, client partners, followers, and the growing IBN Podcast
Series. For more than 18 years, IBN has leveraged this commitment
to provide unparalleled distribution and corporate messaging
solutions to 500+ public and private companies.
To learn more about IBN’s achievements and milestones via a
visual timeline, visit: https://IBN.fm/TimeLine
About Annovis Bio Inc.
Headquartered in Malvern, Pennsylvania, Annovis Bio Inc. is
dedicated to addressing neurodegeneration in diseases such as AD
and PD. The company’s innovative approach targets multiple
neurotoxic proteins, aiming to restore brain function and improve
the quality of life for patients. For more information, visit
www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
About IBN
IBN consists of financial brands introduced to the investment
public over the course of 18+ years. With IBN, we have amassed a
collective audience of millions of social media followers. These
distinctive investor brands aim to fulfill the unique needs of a
growing base of client-partners. IBN will continue to expand our
branded network of highly influential properties, leveraging the
knowledge and energy of specialized teams of experts to serve our
increasingly diversified list of clients.
Through our Dynamic Brand Portfolio (DBP), IBN provides: (1)
access to a network of wire solutions via InvestorWire to reach all
target markets, industries and demographics in the most effective
manner possible; (2) article and editorial syndication to 5,000+
news outlets; (3) Press Release Enhancement to ensure maximum
impact; (4) full-scale distribution to a growing social media
audience; (5) a full array of corporate communications solutions;
and (6) total news coverage solutions.
For more information, please visit
https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the
InvestorBrandNetwork website applicable to all content provided by
IBN, wherever published or re-published:
http://IBN.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications
IBNLos Angeles,
Californiawww.InvestorBrandNetwork.com310.299.1717
OfficeEditor@InvestorBrandNetwork.com
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Nov 2024 to Dec 2024
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Dec 2023 to Dec 2024